Nvidia's recent $50 million investment in an AI startup, Recursion, highlights a strategic move to bolster its GPU sales while potentially inflating its stock price. As Recursion focuses on drug discovery, the partnership could ensure a long-term relationship, locking the startup into Nvidia's ecosystem for future upgrades. The immediate impact was significant, with Recursion's stock soaring by 83%, much to the delight of its investors.
